CD22

Across TCGA pan-cancer cohorts, CD22 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CD22 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD22 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC and LSCC are the cancer types where CD22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.573	.043	2	view →
LSCC	DFS	Median	All	0.848	0.971	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CD22–HNSC (DFS)

Open the HNSC breakdown →